Inhaled Peptide Drugs: Delivery Through the Lungs
Pulmonary & Nasal Peptide Delivery
100 m²
The human lung's alveolar surface area rivals a tennis court, offering a vast, highly vascularized membrane for peptide absorption.
Bellary & Barnett, Diabetes & Vascular Disease Research, 2006
Bellary & Barnett, Diabetes & Vascular Disease Research, 2006
View as imageMost peptide drugs require injection. Their large molecular size, susceptibility to digestive enzymes, and poor oral absorption make swallowing a pill impractical for the vast majority of peptide therapeutics. But the lungs present an alternative route that researchers have pursued for decades: a 100-square-meter surface area, blood vessels within a fraction of a millimeter of inhaled air, and far less enzymatic activity than the gastrointestinal tract.[1]
The concept is straightforward. Formulate a peptide into particles small enough to reach the deepest parts of the lung, and the alveolar epithelium can absorb them into the bloodstream or deliver them directly to diseased lung tissue. The execution is anything but simple. Inhaled insulin reached the market twice, antimicrobial peptides are showing promise against drug-resistant lung infections, and peptide-based carriers are enabling gene therapy in cystic fibrosis models. This article covers the full evidence landscape for inhaled peptide drugs, from clinical successes and failures to the delivery technologies making new applications possible. For related approaches using the nasal route, see our articles on intranasal peptide delivery and nose-to-brain transport.
Key Takeaways
- The lung's alveolar surface area of approximately 100 m² and thin epithelial barrier (under 0.1 mm) make it a viable route for systemic peptide absorption (Bellary & Barnett, 2006)
- Inhaled insulin (Exubera, then Afrezza) demonstrated that pulmonary peptide delivery works clinically, with Afrezza achieving peak action in 40-60 minutes (Bellary & Barnett, 2006)
- Inhaled GLP-1 adsorbed onto Technosphere microparticles produced measurable plasma levels and stimulated insulin secretion in healthy volunteers and type 2 diabetes patients (Marino et al., 2010)
- Inhaled vasoactive intestinal peptide reduced pulmonary artery pressure by 11.5 mmHg in patients with pulmonary hypertension (Leuchte et al., 2008)
- Antimicrobial peptide SET-M33 loaded into polymeric nanoparticles showed sustained antibacterial activity against Pseudomonas aeruginosa with reduced toxicity compared to free peptide (Falciani et al., 2020)
- Optimal alveolar deposition requires aerosol particles between 0.5 and 3 micrometers; particles outside this range deposit in the throat or are exhaled (Shoyele & Cawthorne, 2006)
Why the Lungs Are an Ideal Target for Peptide Delivery
Peptide drugs face a fundamental delivery problem. Oral administration subjects them to stomach acid and proteolytic enzymes that break peptide bonds within minutes. Injection works but creates compliance issues, especially for chronic conditions requiring daily dosing. The lungs offer a set of anatomical advantages that no other non-invasive route can match.[1]
The alveolar epithelium is extraordinarily thin, measuring less than 0.1 mm across most of the gas-exchange surface. Beneath it lies a dense capillary network that receives the entire cardiac output. This combination of vast surface area and minimal diffusion distance allows molecules to pass from inhaled air to arterial blood rapidly.[2]
Compared to the gastrointestinal tract, the lung has substantially lower protease activity. While the GI tract deploys pepsin, trypsin, chymotrypsin, and numerous brush-border peptidases, the alveolar surface has fewer enzymatic barriers to peptide integrity.[3] This matters for peptides that would be destroyed within seconds of oral ingestion.
Pulmonary delivery also enables local targeting. For lung diseases like pulmonary hypertension, cystic fibrosis, or bacterial pneumonia, delivering the peptide directly to the affected tissue achieves higher local concentrations while reducing systemic exposure and side effects. This dual capability, local treatment and systemic absorption, makes the lungs uniquely versatile as a delivery route.[4]
The Inhaled Insulin Story: Proof That Pulmonary Peptide Delivery Works
Insulin was the first peptide to demonstrate that pulmonary delivery could reach clinical practice. Exubera, developed by Pfizer and Nektar Therapeutics, received FDA approval in 2006 as the first inhaled insulin product. Clinical trials showed efficacy comparable to subcutaneous rapid-acting insulin for mealtime glucose control.[1]
The pharmacology was sound. Insulin absorbed through the alveolar epithelium reached the bloodstream within minutes, producing a pharmacokinetic profile suitable for prandial coverage. The pulmonary route bypassed the GI tract entirely, and the rich vascularity of the alveolar surface provided consistent absorption.[1]
Exubera failed commercially. Pfizer withdrew it from the market in October 2007, barely a year after launch. The device was bulky, dosing was imprecise compared to injection pens, and clinicians worried about long-term pulmonary safety, particularly small declines in FEV1 and an unexplained signal of increased lung cancer cases. Sales never approached projections.
MannKind Corporation's Afrezza, approved in 2014, took a different technological approach. It uses Technosphere microparticles made from fumaryl diketopiperazine (FDKP), a small molecule that self-assembles into porous microspheres at low pH. Insulin adsorbs onto these particles, which dissolve rapidly upon reaching the neutral pH of the alveolar surface. The result is faster absorption than Exubera achieved: peak action in 40-60 minutes with a duration of 2-3 hours. A cough occurs in up to 27% of patients, generally mild and decreasing over time.[1]
The inhaled insulin story demonstrates both the potential and the difficulty of pulmonary peptide delivery. The biology works. The engineering and commercial execution determine success or failure.
One persistent limitation across both products: bioavailability. Inhaled insulin achieves roughly 10-15% bioavailability relative to subcutaneous injection, meaning patients inhale substantially more insulin than they would inject. This lower efficiency reflects the multiple barriers between the inhaler mouthpiece and the bloodstream: upper airway deposition losses, mucociliary clearance, macrophage uptake, and surfactant interactions all reduce the fraction that reaches systemic circulation.[3] Despite this, the clinical outcomes demonstrated that even 10-15% bioavailability is sufficient for therapeutic effect when dosing is adjusted accordingly.
Inhaled GLP-1: Metabolic Peptides Through the Lungs
Glucagon-like peptide-1 (GLP-1) has a half-life of approximately 2 minutes in circulation, making it a challenging candidate for any delivery route. MKC253, developed by MannKind, used the same Technosphere platform as Afrezza to deliver native GLP-1 (7-36 amide) by inhalation.[5]
In a proof-of-concept trial in healthy volunteers and patients with type 2 diabetes, inhaled GLP-1 produced measurable plasma concentrations within minutes of administration. The pharmacokinetic-pharmacodynamic analysis showed a clear relationship between inhaled GLP-1 levels and subsequent insulin secretion. This is notable because it demonstrated that even a peptide with an extremely short systemic half-life could be absorbed through the lungs in pharmacologically relevant quantities.[5]
More recently, researchers have explored inhaled delivery of GLP-1 receptor agonists using nanoparticle formulations. Liu et al. (2025) engineered inhalable nanoparticles with optimized surface hydrophilicity to deliver GLP-1 receptor agonists to the lungs, achieving precision targeting that could reduce the systemic side effects (primarily nausea and vomiting) that limit current injectable GLP-1RA therapies.[6]
Hamad et al. (2025) developed dual-sensitive gelatin-coated chitosan microparticles for pulmonary delivery of semaglutide. The microparticles responded to both pH and enzymatic triggers, releasing semaglutide at the alveolar surface while protecting it during transit through the upper airways.[7] These approaches represent a shift from delivering native peptides (which are rapidly degraded) to delivering long-acting analogs through the lungs. For broader context on GLP-1 receptor agonists, see our article on GLP-1 drugs and heart disease.
Vasoactive Intestinal Peptide for Pulmonary Hypertension
Pulmonary hypertension is a condition where delivering the drug directly to the pulmonary vasculature makes biological sense. Vasoactive intestinal peptide (VIP, marketed as aviptadil) is a potent vasodilator and anti-inflammatory peptide that is deficient in the lungs of patients with idiopathic pulmonary arterial hypertension.[8]
Leuchte et al. (2008) tested inhaled VIP in patients with pulmonary hypertension. A single inhalation reduced mean pulmonary artery pressure by 11.5 mmHg, decreased pulmonary vascular resistance, and increased cardiac output. The hemodynamic effects were comparable to inhaled iloprost (a prostacyclin analog already approved for this indication) but without the systemic hypotension that limits iloprost's utility. VIP also increased mixed venous oxygen saturation, indicating improved cardiac function.[8]
This trial exemplifies the advantage of pulmonary targeting: delivering a vasodilatory peptide directly to the vessels it needs to dilate, rather than relying on systemic circulation to carry it there. The approach avoids the dose-limiting systemic vasodilation that plagues many pulmonary hypertension treatments.
The rationale extends to VIP's mechanism. In idiopathic pulmonary arterial hypertension, VIP concentrations in lung tissue are reduced, and VIP receptors (VPAC-1 and VPAC-2) are downregulated. Inhaled delivery restores VIP directly to the deficient tissue at concentrations that would be difficult to achieve systemically without causing hypotension, diarrhea, and other side effects mediated by VIP receptors throughout the body.[8]
Antimicrobial Peptides: Fighting Lung Infections Directly
Bacterial pneumonia, particularly infections caused by multidrug-resistant organisms, represents one of the most compelling cases for inhaled peptide therapy. The lung already produces its own antimicrobial peptides (AMPs) as part of innate immune defense. Delivering additional or modified AMPs directly to the site of infection could bypass the resistance mechanisms that have rendered conventional antibiotics increasingly ineffective. For a comprehensive overview of how these molecules work, see our article on how antimicrobial peptides kill bacteria.[9]
LL-37 and Nanogel Formulations
LL-37, the only human cathelicidin, plays a central role in airway defense. It kills bacteria by disrupting membrane integrity and also modulates immune responses. However, free LL-37 has poor pharmacokinetics when administered to the lungs, being rapidly cleared and potentially toxic at high concentrations.[10]
Kłodzińska et al. (2025) addressed this by encapsulating LL-37 in hyaluronic acid nanogels for pulmonary deposition. The nanogel formulation improved pharmacokinetics and biodistribution compared to free LL-37, extending the peptide's residence time in lung tissue and reducing off-target accumulation. This approach tackles two problems simultaneously: protecting the peptide from degradation and controlling its release to maintain therapeutic concentrations without toxicity.[10]
SET-M33 Nanoparticles for Pseudomonas
Falciani et al. (2020) loaded the antimicrobial peptide SET-M33 into polymeric nanoparticles and aerosolized them for delivery to the lungs. The encapsulated peptide maintained long-lasting antimicrobial activity against Pseudomonas aeruginosa while showing substantially less toxicity than the free peptide in both in vitro and in vivo models. The nanoparticle formulation provided controlled release, sustaining effective concentrations over time rather than delivering a single burst followed by rapid clearance.[11]
Pseudomonas aeruginosa lung infections are a leading cause of morbidity in cystic fibrosis patients and a common cause of ventilator-associated pneumonia. The bacteria's biofilm-forming ability makes it resistant to many systemic antibiotics, but direct delivery of AMPs to the lung surface could achieve concentrations that penetrate biofilms at the site of infection. For the broader context on AMPs and antibiotic resistance, see antimicrobial peptides as alternatives to antibiotics and defensins in your lungs.
Delivery Technologies: Getting Peptides to the Alveoli
The engineering challenge of pulmonary peptide delivery is not just formulating the peptide. It is producing an aerosol with the right particle characteristics to reach the alveoli rather than depositing in the throat or being exhaled.
Particle Size and Deposition
Aerosol particles must have an aerodynamic diameter between 0.5 and 3 micrometers for optimal alveolar deposition. Particles larger than 5 micrometers impact in the oropharynx and are swallowed. Particles smaller than 0.5 micrometers may be exhaled without depositing at all.[3] This narrow window creates strict requirements for formulation and device design.
Dry Powder Inhalers
Dry powder inhalers (DPIs) store the peptide as a solid formulation, which can improve stability compared to liquid formulations. Spray drying and spray freeze drying are the two primary manufacturing methods for creating inhalable peptide powders. Both must preserve the peptide's three-dimensional structure while producing particles in the correct size range.[12]
Excipients play a critical role. Trehalose, mannitol, and leucine are commonly used as stabilizers and dispersibility enhancers. The Technosphere platform used in Afrezza takes a different approach, using self-assembling FDKP microparticles as the carrier. These dissolve at the alkaline pH of the alveolar surface, releasing the adsorbed peptide rapidly.[12]
Nanoparticle Formulations
Nanoparticles offer advantages for pulmonary peptide delivery that conventional powder or liquid formulations cannot match. They protect the peptide from enzymatic degradation, enable controlled release, and can be engineered to evade mucociliary clearance.[13]
Chintapula et al. (2022) demonstrated that supramolecular peptide nanofibers combined with PLGA nanoparticles created composite systems with enhanced pulmonary drug delivery. The self-assembling peptide nanofibers provided structural scaffolding while the PLGA component enabled sustained release of the encapsulated drug.[13]
Nebulizers for Larger Peptides
Nebulizers convert liquid formulations into aerosol droplets and remain the preferred device for larger peptides and proteins that cannot withstand the shear forces of DPI formulation. Wang et al. (2024) used nebulized delivery to administer peptide-modified DNA origami structures for acute lung injury, demonstrating that even complex peptide-conjugate systems can be aerosolized effectively.[14]
Overcoming the Barriers to Pulmonary Peptide Delivery
Despite the lung's anatomical advantages, several biological barriers reduce the efficiency of pulmonary peptide absorption. Understanding these barriers is essential for designing formulations that achieve therapeutic concentrations.[4]
Mucociliary Clearance
The conducting airways (trachea through terminal bronchioles) are lined with mucus-producing goblet cells and ciliated epithelium. This mucociliary escalator physically removes deposited particles within hours, transporting them to the pharynx where they are swallowed. Peptides deposited in the conducting airways rather than the alveoli are largely lost to this mechanism.[4]
Alveolar Macrophages
Macrophages in the alveolar space actively phagocytose particles. Particles between 1 and 5 micrometers are most efficiently engulfed. Nanoparticle formulations under 200 nanometers can partially evade macrophage uptake, as can particles coated with PEG or other "stealth" polymers.[4]
Pulmonary Surfactant
The alveolar surface is coated with pulmonary surfactant, a mixture of phospholipids and surfactant proteins that reduces surface tension to prevent alveolar collapse. Peptides can adsorb to surfactant components, reducing the free fraction available for absorption. This interaction is peptide-specific and difficult to predict without empirical testing.[3]
Enzymatic Degradation
While the lung has less protease activity than the GI tract, it is not protease-free. Alveolar macrophages, epithelial cells, and the surfactant layer all contain peptidases that can degrade therapeutic peptides. Strategies to counter this include PEGylation, co-administration of protease inhibitors, and encapsulation in nanoparticles that shield the peptide until release at the absorption site.[4]
Absorption Enhancement
Chemical modification of peptides (PEGylation, lipidation, cyclization) and incorporation of absorption enhancers can increase the fraction of inhaled peptide that reaches the bloodstream. For peptides intended for systemic delivery rather than local lung treatment, bioavailability remains a major challenge.[4]
PEGylation deserves particular attention. Attaching polyethylene glycol chains to peptides reduces their recognition by proteases and macrophages, extending residence time in the lung. PEGylated peptides also show reduced adsorption to pulmonary surfactant components. The trade-off is that PEGylation increases molecular weight, which can slow absorption across the alveolar epithelium. Finding the optimal PEG chain length for a given peptide requires balancing protection against absorption rate.[4]
Absorption enhancers represent another strategy. Compounds like sodium caprate, chitosan derivatives, and cyclodextrins can transiently increase epithelial permeability, allowing larger peptides to cross the alveolar barrier more efficiently. Safety is the primary concern: any enhancer that disrupts epithelial integrity must do so reversibly and without triggering inflammation in tissue that is chronically exposed with each dose.[2]
Peptides as Carriers for Lung-Targeted Gene Therapy
Beyond using the lungs to deliver peptide drugs, peptides themselves are being used as delivery vehicles for nucleic acid therapies targeting lung diseases. This dual role, peptides as both cargo and carrier, represents one of the most active areas of pulmonary drug delivery research.
KL4 Peptide for mRNA Delivery
Qiu et al. (2019) demonstrated that PEGylated synthetic KL4 peptide, a surfactant-mimetic sequence, could formulate mRNA into dry powder suitable for pulmonary delivery. The KL4 peptide's amphipathic structure allowed it to complex with mRNA while also interacting favorably with pulmonary surfactant at the alveolar surface. The resulting dry powder formulation achieved effective mRNA expression in lung tissue.[15]
Peptide-Targeted Lipid Nanoparticles for Cystic Fibrosis
Soto et al. (2024) discovered peptide ligands that mediate delivery of mRNA-loaded lipid nanoparticles specifically to cystic fibrosis lung epithelia. By decorating LNPs with these targeting peptides, the researchers achieved selective delivery to the cells that need CFTR gene correction, rather than distributing the therapy throughout the lung indiscriminately. This peptide-targeting approach could improve the efficiency of mRNA therapies for cystic fibrosis, where the affected cells represent a small fraction of total lung epithelium.[16]
Cell-Penetrating Peptides
TAT peptide, derived from HIV-1 trans-activator protein, is one of the most studied cell-penetrating peptides. Drago et al. (2023) used TAT-decorated polyplexes for inhaled delivery of siRNA in an asthma model. The TAT peptide facilitated cellular uptake of the siRNA cargo in airway epithelial cells, enabling gene silencing of inflammatory targets directly in the lung.[17] This approach uses the peptide not as the therapeutic agent itself, but as a molecular key that unlocks cellular entry for nucleic acid cargo.
The Broader Landscape of Peptide-Mediated Lung Delivery
These examples share a common thread: peptides are uniquely suited as delivery vehicles for pulmonary applications because their sequences can be engineered to interact with specific features of the lung environment. Surfactant-mimetic peptides like KL4 work with rather than against the lung's natural surfactant layer. Targeting peptides identified through phage display or computational screening can direct cargo to specific cell types within the lung. Cell-penetrating peptides overcome the cellular uptake barrier that limits many nucleic acid therapies.[15]
The convergence of peptide engineering and pulmonary drug delivery is producing increasingly sophisticated systems where peptides serve multiple functions simultaneously: stabilizing cargo during aerosolization, navigating biological barriers in the lung, targeting specific cell populations, and facilitating intracellular delivery. For more on peptide delivery challenges across different routes, see our articles on intranasal peptide delivery and nose-to-brain transport.
The Bottom Line
Pulmonary peptide delivery has moved from concept to clinical reality with inhaled insulin, while newer applications in antimicrobial therapy, pulmonary hypertension treatment, and lung-targeted gene therapy are accumulating preclinical and early clinical evidence. The lung's large surface area, thin epithelial barrier, and relatively low protease activity make it a viable alternative to injection for peptides, though formulation challenges around particle size, stability, and absorption efficiency remain substantial engineering problems that determine whether any given inhaled peptide reaches therapeutic concentrations.